HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $128,228,843 | +332.1% | 3,356,776 | +308.0% | 0.06% | +358.3% |
| Q2 2023 | $29,675,655 | -4.7% | 822,724 | +1.0% | 0.01% | -7.7% |
| Q1 2023 | $31,123,666 | -33.1% | 814,969 | -0.4% | 0.01% | -38.1% |
| Q4 2022 | $46,538,169 | +29.0% | 817,894 | -10.3% | 0.02% | +23.5% |
| Q3 2022 | $36,064,000 | -16.7% | 912,099 | -7.3% | 0.02% | -15.0% |
| Q2 2022 | $43,306,000 | +12.4% | 984,234 | +1.9% | 0.02% | +33.3% |
| Q1 2022 | $38,519,000 | +3.0% | 965,871 | +3.8% | 0.02% | +15.4% |
| Q4 2021 | $37,413,000 | +16.7% | 930,451 | +18.1% | 0.01% | 0.0% |
| Q3 2021 | $32,058,000 | +28.5% | 788,058 | +43.4% | 0.01% | +30.0% |
| Q2 2021 | $24,957,000 | +56.0% | 549,602 | +43.2% | 0.01% | +42.9% |
| Q1 2021 | $15,998,000 | -14.8% | 383,732 | -12.7% | 0.01% | -22.2% |
| Q4 2020 | $18,768,000 | +153.2% | 439,417 | +55.8% | 0.01% | +125.0% |
| Q3 2020 | $7,413,000 | -16.8% | 282,076 | -15.1% | 0.00% | -20.0% |
| Q2 2020 | $8,905,000 | +55.8% | 332,160 | +4.5% | 0.01% | +25.0% |
| Q1 2020 | $5,717,000 | -2.4% | 317,760 | -3.8% | 0.00% | +33.3% |
| Q4 2019 | $5,856,000 | +11.7% | 330,260 | -2.3% | 0.00% | 0.0% |
| Q3 2019 | $5,243,000 | -9.7% | 338,060 | 0.0% | 0.00% | -25.0% |
| Q2 2019 | $5,808,000 | +13.7% | 338,060 | +6.6% | 0.00% | +33.3% |
| Q1 2019 | $5,107,000 | +10.6% | 317,210 | +0.5% | 0.00% | 0.0% |
| Q4 2018 | $4,617,000 | -12.0% | 315,610 | +9.3% | 0.00% | 0.0% |
| Q3 2018 | $5,248,000 | +6.1% | 288,824 | -1.5% | 0.00% | 0.0% |
| Q2 2018 | $4,946,000 | -7.7% | 293,184 | +7.2% | 0.00% | -25.0% |
| Q1 2018 | $5,360,000 | -2.6% | 273,584 | +0.7% | 0.00% | 0.0% |
| Q4 2017 | $5,504,000 | +79.3% | 271,654 | +53.7% | 0.00% | +100.0% |
| Q3 2017 | $3,069,000 | +35.5% | 176,694 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $2,265,000 | +3.3% | 176,694 | +4.4% | 0.00% | 0.0% |
| Q1 2017 | $2,193,000 | +28.0% | 169,194 | -2.4% | 0.00% | +100.0% |
| Q4 2016 | $1,713,000 | -18.2% | 173,394 | 0.0% | 0.00% | -50.0% |
| Q3 2016 | $2,095,000 | +40.0% | 173,394 | 0.0% | 0.00% | +100.0% |
| Q2 2016 | $1,496,000 | -8.9% | 173,394 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $1,642,000 | -45.5% | 173,394 | -0.4% | 0.00% | -66.7% |
| Q4 2015 | $3,015,000 | +26.5% | 174,004 | -2.0% | 0.00% | +50.0% |
| Q3 2015 | $2,384,000 | -46.5% | 177,494 | -10.0% | 0.00% | -50.0% |
| Q2 2015 | $4,453,000 | +58.1% | 197,214 | 0.0% | 0.00% | +100.0% |
| Q1 2015 | $2,816,000 | +48.0% | 197,214 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $1,903,000 | +6.0% | 197,214 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $1,795,000 | -7.9% | 197,214 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $1,948,000 | -18.1% | 197,214 | +5.3% | 0.00% | 0.0% |
| Q1 2014 | $2,378,000 | -15.3% | 187,217 | +0.0% | 0.00% | -33.3% |
| Q4 2013 | $2,806,000 | +35.8% | 187,214 | 0.0% | 0.00% | +50.0% |
| Q3 2013 | $2,067,000 | +38.7% | 187,214 | -0.3% | 0.00% | 0.0% |
| Q2 2013 | $1,490,000 | – | 187,705 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |